*** BiondVax to Showcase its CDMO services at this week’s Biomed Conference in Tel Aviv *** BiondVax Pharmaceuticals will be attending the Biomed Conference in Tel Aviv from May 16-18 to showcase its boutique end-to-end CDMO services at booth #3D. BiondVax's CDMO offers a comprehensive range of services and assets, including: - cGMP manufacturing of biologics at FDA and EMA standards - State-of-the-art laboratories for manufacturing process development & scale-up - Deep pharma experience and leadership to help accelerate your product forward BiondVax's CDMO services are designed to meet the needs of pharmaceutical and biotechnology companies of all sizes. The company's team of experienced professionals is committed to providing its customers with the highest level of quality and service. To learn more about BiondVax's CDMO services: - Visit the company's booth 3D at the Biomed Conference (https://lnkd.in/gfvUNHd) - Visit https://lnkd.in/djWmZnt5. - Download the attached brochure
Scinai Immunotherapeutics Ltd.’s Post
More Relevant Posts
-
Yesterday, Scinai Immunotherapeutics Ltd. filed its #financial_reports for 2023 and provided a #business_update. It was a strong year in which we continued progressing our drug development programs while demonstrating growth in our new #CDMO business unit. 𝑆𝑜𝑚𝑒 2023 ℎ𝑖𝑔ℎ𝑙𝑖𝑔ℎ𝑡𝑠 𝑖𝑛𝑐𝑙𝑢𝑑𝑒: ✅ 𝐖𝐞 𝐰𝐞𝐫𝐞 𝐚𝐛𝐥𝐞 𝐭𝐨 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭𝐥𝐲 𝐫𝐞𝐝𝐮𝐜𝐞 𝐨𝐮𝐫 𝐞𝐱𝐩𝐞𝐧𝐬𝐞𝐬 𝐚𝐧𝐝 𝐫𝐮𝐧𝐧𝐢𝐧𝐠 𝐜𝐨𝐬𝐭𝐬 𝐢𝐧 𝟐𝟎𝟐𝟑. We also raised approximately $3m in investments and secured a non-dilutive grant from the Israel Innovation Authority, which covers 66% of a NIS 3.5M project to develop our CDMO business unit. 📈 𝐎𝐮𝐫 𝐂𝐃𝐌𝐎 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐮𝐧𝐢𝐭 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐬 𝐭𝐨 𝐠𝐚𝐢𝐧 𝐭𝐫𝐚𝐜𝐭𝐢𝐨𝐧, 𝐚𝐬 𝐨𝐮𝐫 𝐟𝐢𝐫𝐬𝐭 𝐚𝐜𝐭𝐢𝐯𝐞 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐨𝐟𝐟𝐞𝐫𝐢𝐧𝐠. In the first four months of 2024, we were able to secure $500K in CDMO work orders and expect to generate approximately $1.25M in revenues for the year, with several potential contracts in advanced discussions. ✅ 𝐖𝐞'𝐯𝐞 𝐛𝐞𝐞𝐧 𝐚𝐜𝐭𝐢𝐯𝐞𝐥𝐲 𝐦𝐚𝐫𝐤𝐞𝐭𝐢𝐧𝐠 𝐨𝐮𝐫 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐚𝐭 𝐦𝐚𝐣𝐨𝐫 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐜𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞𝐬, including the upcoming Biomed Israel 2024 conference next week. ✅ 𝐈𝐧 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟑, 𝐰𝐞 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐝 𝐩𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐢𝐧 𝐚 𝐩𝐬𝐨𝐫𝐢𝐚𝐭𝐢𝐜 𝐡𝐮𝐦𝐚𝐧 𝐬𝐤𝐢𝐧 𝐦𝐨𝐝𝐞𝐥, 𝐄𝐱-𝐕𝐢𝐯𝐨. The statistically significant results demonstrated the potential for Scinai's anti-IL-17 NanoAbs to noticeably improve psoriatic skin lesions as indicated by skin viability and structural integrity. 💡 𝐍𝐞𝐱𝐭 𝐦𝐨𝐧𝐭𝐡 (𝐉𝐮𝐧𝐞 𝟐𝟎𝟐𝟒), 𝐰𝐞 𝐚𝐧𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞 𝐫𝐞𝐜𝐞𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐢𝐧𝐚𝐥 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐨𝐟 𝐨𝐮𝐫 𝐢𝐧-𝐯𝐢𝐯𝐨 𝐚𝐧𝐢𝐦𝐚𝐥 𝐬𝐭𝐮𝐝𝐲 𝐟𝐨𝐫 𝐚𝐧𝐭𝐢-𝐈𝐋-𝟏𝟕 𝐍𝐚𝐧𝐨𝐀𝐛𝐬 𝐢𝐧 𝐩𝐬𝐨𝐫𝐢𝐚𝐬𝐢𝐬 𝐚𝐧𝐝 𝐥𝐨𝐨𝐤𝐢𝐧𝐠 𝐟𝐨𝐫𝐰𝐚𝐫𝐝 𝐭𝐨 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐆𝐞𝐫𝐦𝐚𝐧𝐲'𝐬 Paul-Ehrlich-Institut 𝐭𝐨 𝐝𝐢𝐬𝐜𝐮𝐬𝐬 𝐩𝐫𝐞𝐩𝐚𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐚 𝐟𝐢𝐫𝐬𝐭-𝐢𝐧-𝐡𝐮𝐦𝐚𝐧 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥, which is planned to commence in 2025. Our innovation pipeline for 2024 includes advancing additional NanoAbs for autoimmune diseases such as #asthma and wet #AMD. For detailed financial results and business updates, check out our Financial Reports here: https://lnkd.in/d-nqZPeF #Biopharma #Innovation #CDMO #Immunotherapy #Biotechnology
To view or add a comment, sign in
-
Last Thursday, we celebrated the latest partnership in our #CDMO division, with a toast in our Jerusalem office. Yanir Aldouby, Prof. Yechezkel Barenholz, and the AYANA PHARMA LTD team were there to join us. AYANA PHARMA LTD, a pharma company developing #Liposomal #Therapeutics Treatment, has signed a 5-year MSA (Master Service Agreement) with Scinai Immunotherapeutics Ltd. #Bioservices. Ayana will benefit from our drug development and #cGMP manufacturing services, including encapsulating drug substances of various partners of Ayana into Ayana's proprietary liposomal drug delivery system. "We are pleased to welcome Ayana as a client. We are proud that Prof. Barenholz and Ayana recognized the end-to-end CDMO capabilities of Scinai Bioservices as the best fit to support their liposomal product portfolio drug development needs,” said Elad Mark, Scinai's COO. After the toast, Prof. Barenholtz Yehezkel provided an inspiring educational presentation about the latest innovative discoveries in the area of liposomal therapeutics. Amir Reichman Liat Halpert Dalit Fischer Tehila Sonnenfeld #CDMO #Bioservices #partnership #growth #biotech #cGMPmanufacturing #innovation
To view or add a comment, sign in
-
Scinai Immunotherapeutics Ltd. is excited to attend the Biomed Israel 2024 conference on 21-23 May. We invite investors, partners, and biopharma developers to meet us! Stop by our booth #60 to: ⚛️ Hear more about our promising drug development program for our innovative Anti-IL-17A/F NanoAb 📈 Discover how our end-to-end boutique CDMO can optimize your process development and streamline your project. 🤝 Meet our distinguished Biopharma team including CEO, Amir Reichman; COO, Elad Mark; CTO Dalit Fischer; and Head of BD & Sales, Liat Halpert, ready to answer all your questions. We look forward to seeing you there. Reach out to us to schedule a meeting at bd@scinai.com #biomed2024 #biotech #bioservices #innovation #psoriasis #pharma #pipelineinnovation #drugdevelopment #drugmanufacturing #cGMPProduction #partnership
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in
-
Scinai Immunotherapeutics Ltd. are excited to attend the Biomed Israel 2024 conference on 21-23 May. We invite #investors, #partners, and #biopharma #developers to meet us! Stop by our booth #60 to: ⚛️ Hear more about our promising drug development program for our innovative Anti-IL-17A/F #NanoAb 📈 Discover how our end-to-end boutique #CDMO can optimize your process development and streamline your project. 🤝 Meet our distinguished Biopharma team including CEO, Amir Reichman; COO, Elad Mark; CTO Dalit Fischer; and Head of BD & Sales, Liat Halpert, ready to answer all your questions. We look forward to seeing you there. Reach out to us to schedule a meeting at bd@scinai.com #biotech #bioservices #innovation #psoriasis #pharma #pipelineinnovation #drugdevelopment #drugmanufacturing #cGMPProduction #partnership
To view or add a comment, sign in
-
Exciting Developments at Scinai Immunotherapeutics Ltd.: Join Us for the Journey! We’re thrilled to share that #Scinai is on the move with a host of exciting new developments. On May 8th, we invite investors worldwide to join our CEO, Amir Reichman, at the Aegis Capital Corp. Virtual Conference for an exclusive insight into our journey. 👉 Tune in at 9:00 am EDT (16:00 IDT) to hear about the promising drug development program of our innovative Anti-IL-17A/F #NanoAb, aimed for local treatment of plaque #psoriasis. 👉 Amir will also provide an overview of our thriving #CDMO business unit branded “Scinai Bio-Services”. Through our CDMO unit, we offer comprehensive biological drug development and manufacturing solutions, supporting emerging biopharma companies every step of the way. 📈 We’re honored to stand alongside a distinguished lineup of biotech innovators at this event. Our heartfelt thanks goes to the team at Aegis Capital Corp. for this opportunity. Don’t miss out on this exciting event. Sign up here to join the session: https://lnkd.in/dQ3Q3nAg Chemomab Therapeutics Humanigen Genenta Science NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) NEXGEL Advanced Hydrogel Solutions Volcon | ePowersports RenovoRx RedHill Biopharma Ltd. Bionomics Ltd OKYO Pharma Biotricity Inc. (NASDAQ:BTCY) Foresight Group ParaZero Drone Safety Systems Pasithea Therapeutics N2OFF Inc. Sharps Technology, Inc. Iterum Therapeutics plc Cyngn Artelo Biosciences, Inc. Equillium, Inc. NLCP Pyxis Oncology SenesTech Inc. LogicMark Soligenix, Inc. Atara Biotherapeutics Upexi, Inc (NASDAQ: UPXI) Ocuphire Pharma Helius Medical Technologies, Inc. Reviva Pharmaceuticals Virpax Pharmaceuticals Inc. (Nasdaq:VRPX) Single Point Capital Amesite Workspot, Inc Rockwell Medical, Inc. #investorsupdate #businessupdate #newdevelopment #biotech #pipelineinnovation #bioservices #drugdevelopment #drugmanufacturing #cGMPProduction #partnership #innovation
To view or add a comment, sign in
-
Scinai Immunotherapeutics’ team is humbled to have had the opportunity to present today and to participate, along with other world-class dermatologists and dermatology drug developers, in the 5th Annual Dermatology Drug Development Summit in Berlin. Participating in this summit is immensely valuable for our team, offering us unparalleled insights into the latest advancements and trends in dermatology. It also provides us with a unique platform to showcase our innovative work and to engage in meaningful discussions with leading experts in the field. We believe the connections made and the knowledge gained during this event will play a crucial role in shaping the future of dermatological treatment and in advancing our mission to develop ground breaking therapies for patients worldwide.
To view or add a comment, sign in
-
Scinai continues making waves - and this time we will showcase our novel biological local therapeutic for Plaque Psoriasis at the 5th Annual Dermatology Drug Development Summit, which will take place in Berlin Germany between April 17-19. In the conference, our CSO Dr. Tammy Ben Yedidia will present together with Prof. Michael Schön, a world-renowned dermatologist of the University Medical Center Gottingen, Germany a presentation titled: Elevating Dermatological Drug Development Through Advanced Inflammatory Marker Targeting Methodology. In addition, our CEO Mr. Amir Reichman will be panel participant in the panel discussion titled: “Route of Administration & Formulations: How Can We Improve?" https://lnkd.in/d46453HA https://lnkd.in/deqn7cHV Boutique Biologics CDMO — Scinai
To view or add a comment, sign in
-
We are pleased to announce Ayana Pharma signed a 5-year drug development and cGMP manufacturing agreement with our CDMO unit Including aseptic filling, quality assurance, and encapsulation of drug substances of various partners of Ayana into Ayana’s proprietary liposomal drug delivery system. Scinai Press Releases — Scinai https://lnkd.in/dAJGUxfi
static1.squarespace.com
To view or add a comment, sign in
-
Together with ADRES Int'l Biotech Consultation & Execution, we're thrilled to be hosting, for the first time in Israel, a hands-on Aseptic Processing Course in our state-of-the-art biologics manufacturing facility in Jerusalem. Details and registration: https://lnkd.in/d797icbf
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in
3,019 followers